Division of Multispecialty Anesthesiology, 12328Vanderbilt University Medical Center, Nashville, TN, USA.
Anesthesiology, 12328Vanderbilt University Medical Center, Nashville, TN, USA.
Semin Cardiothorac Vasc Anesth. 2022 Dec;26(4):266-273. doi: 10.1177/10892532221104420. Epub 2022 May 26.
. A retrospective case-control study was conducted to assess the feasibility of erector spinae plane (ESP) block as part of a multimodal enhanced recovery program for patients undergoing minimally invasive mitral valve replacement surgery. . This retrospective analysis was conducted at a single center between January and August 2019. 61 patients were included; 23 received ESP and 38 did not. Erector spinae catheters (ESCs) were placed preoperatively, using a loading dose of 30 mL .5% ropivacaine, followed by an infusion of .2% ropivacaine at 10 mL/h throughout the study period. Primary outcome was 48-hour opioid consumption. Secondary outcomes included intraoperative morphine equivalents, extubation within 24 hours, reintubation, ICU length of stay and hospital length of stay and 30-day mortality. . Median [inter-quartile range] of the postoperative morphine milligram equivalents (MMEs) in the first 48 hours was 70[45-121] MMEs in the ESC) group, and 109[70-148] MMEs in the no ESC group (-value = .16). No significant difference was observed in intraoperative morphine equivalents, extubation within 24 hours or ICU length of stay. The ESC group had shorter hospital length of stay (6.0 vs 7.0 days, -value = .043). . This study found a statistically insignificant, though potentially clinically significant reduction in postoperative opioid consumption. A reduced hospital length of stay as well as an acceptable safety profile was also observed in the ESC group. An adequately powered, prospective trial is warranted to accurately assess the potential role for ESP catheters for patients undergoing minimally invasive mitral valve surgery.
一项回顾性病例对照研究评估了竖脊肌平面(ESP)阻滞作为微创二尖瓣置换手术多模式加速康复方案的一部分的可行性。这项回顾性分析在 2019 年 1 月至 8 月在一个单一中心进行。共纳入 61 例患者,其中 23 例接受了 ESP 阻滞,38 例未接受。ESP 导管于术前放置,给予 30ml 0.5%罗哌卡因负荷量,随后在整个研究期间以 10ml/h 的速度输注 0.2%罗哌卡因。主要结局是 48 小时内阿片类药物的消耗量。次要结局包括术中吗啡等效物、24 小时内拔管、再次插管、ICU 住院时间和住院时间以及 30 天死亡率。在 ESC 组,术后 48 小时内吗啡毫克当量(MME)中位数[四分位间距]为 70[45-121]MME,无 ESC 组为 109[70-148]MME(-值=.16)。术中吗啡等效物、24 小时内拔管或 ICU 住院时间无显著差异。ESC 组的住院时间更短(6.0 天 vs 7.0 天,-值=.043)。这项研究发现术后阿片类药物消耗虽有统计学意义但可能具有临床意义的减少。ESC 组也观察到住院时间缩短和可接受的安全性。需要一项充分的、前瞻性试验来准确评估 ESP 导管在微创二尖瓣手术患者中的潜在作用。